Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-5 of 5 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsRoss, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
2019Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionShanmuganathan, N.; Braley, J.; Yong, A.; Hiwase, D.; Yeung, D.; Ross, D.; Hughes, T.; Branford, S.